| Dr Andy Y Jun, PHARM D | |
|
502 Gapway St, Mullins, SC 29574-3414 | |
| (843) 464-0118 | |
| (843) 464-7375 |
| Full Name | Dr Andy Y Jun |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 502 Gapway St, Mullins, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881048361 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 14323 (South Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andy Y Jun, PHARM D 760 Pennywell Ct, Columbia, SC 29229-8439 Ph: (843) 464-0118 | Dr Andy Y Jun, PHARM D 502 Gapway St, Mullins, SC 29574-3414 Ph: (843) 464-0118 |
News Archive
The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial.
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.
The Departments of Pharmacology and Ophthalmology and Visual Sciences at Case Western Reserve University School of Medicine have been awarded a $10.1 million grant from the National Eye Institute (NEI) to research and develop new treatments for diseases of the retina, a leading cause of blindness.
The fifth annual international conference of the African Science Academy Development Initiative (ASADI) will be held Nov. 9-11 in Accra, Ghana, in conjunction with the 50th anniversary of the Ghana Academy of Arts and Sciences. The theme of this year's conference will be improving maternal, newborn, and child health in Africa, which will be discussed by top experts from around the world.
Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with lower urinary tract symptoms (LUTS) due to BPH. Aptocine is also in two Phase 3 clinical trials for solid tumors in the liver as well as preclinical development for prostate cancer.
› Verified 6 days ago
William Brown Jr., PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 310 S Main St, Mullins, SC 29574 Phone: 843-434-1757 Fax: 843-464-1751 | |
Mr. Avery Ethan Lambert, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 236 W Mcintyre St, Mullins, SC 29574 Phone: 843-464-0372 Fax: 843-464-2729 | |
Douglas Ray Floyd, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 502 Gapway St, Mullins, SC 29574 Phone: 843-464-0118 Fax: 843-464-7375 | |
Abby Cooper, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 305 Commerce Dr, Mullins, SC 29574 Phone: 843-423-9411 Fax: 843-423-9424 | |
Mrs. Margaret C Askins, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 502 Gapway St, Mullins, SC 29574 Phone: 843-464-0118 Fax: 843-464-7375 | |
Dr. Daniel Jason Spivey, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 236 W Mcintyre St, Mullins, SC 29574 Phone: 843-464-0372 | |
Dr. Morgan Causey Pierce, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 305 Commerce Dr, Mullins, SC 29574 Phone: 843-423-9411 |